IRIS
SARACENO, ROSITA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 14.952
AS - Asia 1.652
EU - Europa 1.626
SA - Sud America 226
AF - Africa 34
OC - Oceania 18
Continente sconosciuto - Info sul continente non disponibili 5
Totale 18.513
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 14.900
SG - Singapore 616
CN - Cina 523
DE - Germania 228
IT - Italia 224
RU - Federazione Russa 218
UA - Ucraina 213
BR - Brasile 179
FR - Francia 151
HK - Hong Kong 141
IE - Irlanda 135
SE - Svezia 116
VN - Vietnam 102
GB - Regno Unito 98
FI - Finlandia 76
PL - Polonia 61
IN - India 52
KR - Corea 52
JP - Giappone 36
BD - Bangladesh 34
CA - Canada 31
AR - Argentina 17
AU - Australia 17
ES - Italia 16
AE - Emirati Arabi Uniti 13
CO - Colombia 13
NL - Olanda 13
EG - Egitto 12
SK - Slovacchia (Repubblica Slovacca) 12
PH - Filippine 10
ZA - Sudafrica 10
CH - Svizzera 9
KG - Kirghizistan 9
RO - Romania 9
TR - Turchia 9
GR - Grecia 8
IR - Iran 8
MX - Messico 8
PY - Paraguay 8
BE - Belgio 7
AT - Austria 6
IQ - Iraq 6
MA - Marocco 6
PK - Pakistan 6
UZ - Uzbekistan 6
LV - Lettonia 5
RS - Serbia 5
TW - Taiwan 5
CR - Costa Rica 4
CZ - Repubblica Ceca 4
LT - Lituania 4
PT - Portogallo 4
CL - Cile 3
EU - Europa 3
ID - Indonesia 3
MY - Malesia 3
OM - Oman 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AZ - Azerbaigian 2
DK - Danimarca 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
EC - Ecuador 2
HN - Honduras 2
IL - Israele 2
JM - Giamaica 2
NI - Nicaragua 2
PE - Perù 2
PS - Palestinian Territory 2
SN - Senegal 2
VE - Venezuela 2
BH - Bahrain 1
CY - Cipro 1
EE - Estonia 1
GA - Gabon 1
HR - Croazia 1
JO - Giordania 1
KH - Cambogia 1
KY - Cayman, isole 1
LB - Libano 1
MM - Myanmar 1
NG - Nigeria 1
NP - Nepal 1
NZ - Nuova Zelanda 1
SA - Arabia Saudita 1
TH - Thailandia 1
Totale 18.513
Salva come PNG Salva come JPEG
Città #
Woodbridge 4.102
Houston 3.739
Wilmington 3.344
Fairfield 454
Singapore 388
Ann Arbor 348
Chandler 320
Ashburn 304
Jacksonville 185
San Jose 173
Beijing 167
Cambridge 166
Seattle 161
Dublin 135
Hong Kong 135
New York 127
Medford 110
Zhengzhou 92
Dearborn 90
Rome 72
The Dalles 66
Los Angeles 56
Dallas 53
Santa Clara 51
Lawrence 50
Kraków 35
Shanghai 34
Moscow 33
Ho Chi Minh City 32
Boardman 31
Lauterbourg 31
Tokyo 31
Council Bluffs 29
Helsinki 25
Menlo Park 25
Buffalo 24
Hanoi 24
San Diego 21
São Paulo 20
Redondo Beach 18
Munich 17
Mülheim 17
Hefei 16
Norwalk 16
Orem 16
Warsaw 15
Hangzhou 14
Nanjing 14
Redwood City 13
Detroit 12
London 12
Brooklyn 11
Chennai 11
Dubai 11
Guangzhou 11
Milan 11
Montreal 10
Da Nang 9
Kunming 9
Toronto 9
Denver 8
Paris 8
Stockholm 8
Chicago 7
Frankfurt am Main 7
Haiphong 7
Nanchang 7
Palo Alto 7
Phoenix 7
Redmond 7
San Mateo 7
Brussels 6
Columbus 6
Draper 6
Johannesburg 6
Madrid 6
Manchester 6
Poznan 6
Salt Lake City 6
Verona 6
Asunción 5
Bern 5
Bolzano 5
Dhaka 5
Florence 5
Fuzhou 5
Melbourne 5
Mountain View 5
Nuremberg 5
Riga 5
San Francisco 5
Trento 5
Turku 5
University Park 5
Wuhan 5
Amsterdam 4
Ankara 4
Auburn Hills 4
Baghdad 4
Bengaluru 4
Totale 15.784
Salva come PNG Salva come JPEG
Nome #
Crusted scabies in a liver transplant patient mimicking rupioid psoriasis 1.396
Efficacy and safety of infliximab in psoriatic patients over the age of 65 552
Atopic dermatitis and dental manifestations 543
Topical lactoferrin can improve stable psoriatic plaque 501
-174G/C IL-6 gene promoter polymorphism predicts therapeutic response to TNF-α blockers 486
Apremilast for the treatment of psoriasis. 477
Psoriasis Phenotype in Inflammatory Bowel Disease: A Case-Control Prospective Study 477
Oral lichen planus: therapy and phenotype 472
Golimumab in Patients Affected by Moderate to Severe Psoriatic Arthritis: An Open-Label Study in Thirty-Two Patients Previously Treated with Other Biologics 460
New topical treatments for psoriasis 459
Emergence of antinuclear antibodies in psoriatic patients treated with infliximab: personal experience and literature review 457
Profile of certolizumab and its potential in the treatment of psoriatic arthritis 456
Increased levels of IL-17 in tear fluid of moderate-to-severe psoriatic patients is reduced by adalimumab therapy 454
Effect of anti-tumor necrosis factor-alpha therapies on body mass index in patients with psoriasis 451
Adalimumab in the treatment of plaque-type psoriasis and psoriatic arthritis 448
Role of IL-23 in the pathogenesis of psoriasis: A novel potential therapeutic target? 444
Trimethoprim-sulfamethoxazole induced erythrodermic psoriasis 440
The significance of the development of antinuclear antibodies during infliximab treatment 433
Real-life 9-year experience with adalimumab in psoriasis and psoriatic arthritis: results of a single-centre, retrospective study. 422
Prospective assessment of body weight and body composition changes in patients with psoriasis receiving anti-TNF-α treatment 421
Usefulness of QuantiFERON®-TB Gold test in psoriatic patients under treatment with tumour necrosis factor blockers 414
Oral lichen planus: Novel acquisitions in the pathogenesis and treatment 413
Pharmacodynamic assessment of apremilast for the treatment of moderate-to-severe plaque psoriasis 405
Erysipeloid cutaneous metastasis from bladder carcinoma 402
TNF-α antagonists and nail psoriasis: An open, 24-week, prospective cohort study in adult patients with psoriasis 396
Quality of life of psoriatic patients evaluated by a new psychometric assessment tool: PsoDisk 395
Influence and variation of the body mass index in patients treated with etancercept for psoriasis 394
Cyclosporine: a novel therapeutic approach for Burning Mouth Syndrome 391
Prevalence and management of panic attacks during infliximab infusion in psoriatic patients 379
Small molecules and antibodies for the treatment of psoriasis: A patent review (2010–2015) 371
Serum Protein Profile Changes in Psoriatic Patients Undergoing Treatment With Infliximab 365
Does metabolic syndrome influence psoriasis? 364
The role of antinuclear autoantibodies in patients with psoriasis treated with anti-tumor necrosis factor-alpha agents: a retrospective long-term study 358
Tofacitinib for the treatment of moderate-to-severe psoriasis 356
Why 3 mg/kg instead of 5 mg/kg of infliximab should work in psoriatic arthritis? 325
Safety evaluation of apremilast for the treatment of psoriasis 321
A European perspective on the challenges of managing psoriasis 224
Oral lichen planus: Therapy and phenotype 213
308 nm monochromatic excimer light in the treatment of psoriasis 202
Different applications of monochromatic excimer light in skin diseases 189
Efficacy of monochromatic excimer laser radiation (308 nm) in the treatment of early stage mycosis fungoides 173
Treatment of folliculitis with monochromatic excimer light (308 nm). 168
Aphthous, coeliac disease and other dental disorders in childhood 158
Type III juvenile pityriasis rubra pilaris: A successful treatment with infliximab [12] 157
Randomized, within-patient, clinical trial comparing fluorine-synthetic fiber socks with standard cotton socks in improving plantar pustulosis 154
Type III juvenile pityriasis rubra pilaris: a successful treatment with infliximab. 152
Nanomedicine in dermatology: Benefits and emerging applications 145
Comparison of a novel treatment protocol with oral fluconazole vs probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 in the treatment of recurrent vulvovaginal candidiasis 131
Clinical severity instruments 122
Ustekinumab treatment of erythrodermic psoriasis occurring after physical stress: A report of two cases 118
Keratosis punctata palmoplantaris and malignancies: case report 83
Apheresis in the treatment of recalcitrant atopic dermatitis: Case series and review of the literature 65
Totale 18.752
Salva come PNG Salva come JPEG
Categoria #
all - tutte 42.473
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 42.473
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022533 32 59 41 34 14 54 23 21 40 56 28 131
2022/2023815 70 63 37 119 87 153 56 48 98 11 39 34
2023/2024345 34 8 37 18 26 104 21 13 2 7 10 65
2024/2025980 47 193 106 77 34 58 102 36 74 96 98 59
2025/20261.918 166 95 239 184 196 67 261 196 205 149 92 68
2026/20271 1 0 0 0 0 0 0 0 0 0 0 0
Totale 18.752